Board Meeting Details

The meeting was held on Wednesday, July 29, 2026, from 07:00 p.m. to 08:00 p.m.

Key Financial Results - Standalone (Amounts in ₹ lakhs)

Quarter Ended June 30, 2026:

  • Net Sales/Income from Operations: ₹2,684.23
  • Other Income: ₹52.81
  • Total Income: ₹2,737.04
  • Total Expenses: ₹2,081.28
  • Cost of Materials Consumed: ₹1,379.89
  • Purchase of Stock-in-Trade: ₹219.74
  • Changes in Inventories: (₹16.16)
  • Employment Benefit Expenses: ₹97.06
  • Financial Costs: ₹49.15
  • Depreciation and Amortization: ₹69.81
  • Other Expenses: ₹281.79
  • Profit Before Tax: ₹655.76
  • Tax Expense: Current Tax ₹154.00
  • Net Profit for the Period: ₹501.76
  • Paid Up Equity Share Capital (FV ₹10 each): ₹1,193.30
  • Earnings Per Share (Basic & Diluted): ₹4.26

Comparative Figures - Standalone:

  • Quarter Ended March 31, 2026: Net Profit ₹566.10, EPS ₹4.85
  • Quarter Ended June 30, 2025: Net Profit ₹347.59, EPS ₹3.02
  • Year Ended March 31, 2026: Net Profit ₹1,809.27, EPS ₹15.50

Key Financial Results - Consolidated (Amounts in ₹ lakhs)

Quarter Ended June 30, 2026:

  • Revenue from Operations: ₹3,371.84
  • Other Income: ₹57.30
  • Total Income: ₹3,429.14
  • Total Expenses: ₹2,768.52
  • Cost of Materials Consumed: ₹1,198.75
  • Purchase of Stock-in-Trade: ₹228.24
  • Changes in Inventories: ₹602.19
  • Employment Benefit Expenses: ₹168.52
  • Financial Costs: ₹85.60
  • Depreciation and Amortization: ₹162.48
  • Other Expenses: ₹322.73
  • Profit Before Tax: ₹660.62
  • Tax Expense: Current Tax ₹154.00
  • Net Profit for the Period: ₹506.62
  • Minority Interest: ₹3.58
  • Profit for the Period after Minority Interest: ₹503.04
  • Paid Up Equity Share Capital (FV ₹10 each): ₹1,193.30
  • Earnings Per Share (Basic & Diluted): ₹4.27

Comparative Figures - Consolidated:

  • Quarter Ended March 31, 2026: Net Profit ₹672.58, EPS ₹5.76
  • Quarter Ended June 30, 2025: Net Profit ₹306.28, EPS ₹2.66
  • Year Ended March 31, 2026: Net Profit ₹1,904.14, EPS ₹16.32

Audit Review

A Bafna & Associates, Chartered Accountants (Firm Reg. No: 121901W), issued clean limited review reports for both standalone and consolidated financial results. The reviews were conducted in accordance with SRE 2410 and confirmed that the financial results contain no material misstatements and comply with SEBI Listing Regulations.

Subsidiary Information

The consolidated results include the following subsidiaries:

  • TNS Pharma Private Limited (51% holding)
  • TLL Parenterals Limited (51% holding)
  • Trident Mediquip Limited (58.67% holding as of June 30, 2026)
  • TLL Elements Private Limited (100% holding)
  • TLL Wellness Limited (formerly TLL Herbal Limited) (51% holding)

Additional Notes

  • Financial statements prepared in accordance with Indian GAAP and Accounting Standards
  • Figures for previous periods have been re-grouped/re-stated for comparability
  • Company is exempted from IND-AS as it is listed on BSE SME platform
  • No significant impact expected from global health pandemic on carrying amounts of inventories, trade receivables, investments and other financial assets
  • No investor complaints during the period ended June 30, 2026